Against this background, we pursued our research through structural optimization of the 2-furylbenzimidazole derivative IX by the design and synthesis of a novel series of VEGFR-2 inhibitors targeting hepatocellular carcinoma based on the benzimidazole scaffold. The gene discussed is KDR; the disease is hepatocellular carcinoma.